WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant

Leuk Res. 2021 Sep:108:106587. doi: 10.1016/j.leukres.2021.106587. Epub 2021 Apr 30.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Combined Modality Therapy
  • Decitabine / therapeutic use*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / etiology
  • Neoplasm Recurrence, Local / pathology
  • Prognosis
  • Transplantation, Homologous
  • WT1 Proteins / genetics
  • WT1 Proteins / metabolism*

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • WT1 Proteins
  • WT1 protein, human
  • Decitabine